Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of the 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions)

During June 2026, 800 of the 11th Stock Acquisition Rights were exercised and 80,000 shares were delivered. The balance of unexercised rights stood at 8,549 at the end of the month.

Worth reading
66In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
80000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status report for stock acquisition rights with an exercise price adjustment clause

Who receives how much

80,000 new shares; 0 treasury shares transferred

Macquarie Bank Limited (previously issued 11th Stock Acquisition Rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
+0.97%Rate of increase
14,225,000 shares14,305,000Shares

0.97% (80,000 shares delivered across all series / 8,229,900 listed shares outstanding as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price during the month covered was ¥134 or ¥144. The lower limit under the adjustment provisions was not disclosed.
Number of Stock Acquisition Rights
Total issued: 30,000 rights (800 exercised; 8,549 unexercised at the end of the month covered)
Procedures under the Corporate Code of Conduct
Report on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Regulations on Listing of Securities and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Issued on 2 February 2026: 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions); amount not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status report for stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of80,000 new shares; 0 treasury shares transferred
Intended allotteeMacquarie Bank Limited (previously issued 11th Stock Acquisition Rights)
Dilution Rate0.97% (80,000 shares delivered across all series / 8,229,900 listed shares outstanding as of the payment date for the issuance)
Total number of issued shares14,225,000 shares (as of the end of the month preceding the month covered) → 14,305,000 shares (the number of shares outstanding at the end of the preceding month plus the number of new shares delivered during the month covered)
Exercise priceThe exercise price during the month covered was ¥134 or ¥144. The lower limit under the adjustment provisions was not disclosed.
Number of Stock Acquisition RightsTotal issued: 30,000 rights (800 exercised; 8,549 unexercised at the end of the month covered)
Procedures under the Corporate Code of ConductReport on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Regulations on Listing of Securities and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingIssued on 2 February 2026: 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions); amount not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status for June 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori